Results 61 to 70 of about 31,601 (273)

Emergence of the Biosimilar Sector and Opportunities of Developing Country Suppliers [PDF]

, 2011
As biologic products begin to come off-patent, a market is emerging for biosimilars (also known as biogenerics or follow-on biologics). Firms from emerging countries such as India and China have dominated the production of active ingredients in ...
Huzair, Farah, Kale, Dinar
core  

Krónikus betegségek biológiai terápiájának alkalmazásával kapcsolatos gazdasági megfontolások = Economic consideration of the implementation of biotechnological therapies in chronic diseases [PDF]

, 2014
Disszertációmban egyes krónikus betegségekben alkalmazott biológiai terápiák gazdasági, pénzügyi és költségvetési hatásaival foglalkoztam. Célkitűzés: A biológiai gyógyszerek terápiás alkalmazásáról rendelkezésre álló tudás mind Magyarországon, mind a ...
Balogh, Orsolya
core   +1 more source

Measuring the Impact of the Substitution of Innovator Biologics With Biosimilars on Uptake and Costs Among Ontario Public Drug Benefit Recipients

Clinical Pharmacology &Therapeutics, EarlyView.
In Ontario, biologics have historically represented a small proportion of public drug claims but a large proportion of spending. Biosimilars, lower cost alternatives to biologics, offer a potential solution to the rising spending on biologics. From March 2023 to January 2024, the Ontario Ministry of Health required public drug program beneficiaries on ...
Anita Iacono, Martin K. H. Ho, Joanna Yang, Tonya Campbell, William Wynne, Dana Shearer, Lene Andersen, Eric Majer, Shaleesa Ledlie, Mina Tadrous, Tara Gomes   +10 more
wiley   +1 more source

Uptake of Biosimilar Infliximab in the UK, France, Japan, and Korea: Budget Savings or Market Expansion Across Countries?

Frontiers in Pharmacology, 2020
ObjectiveTo compare the market dynamics of biosimilar infliximab among four Organization for Economic Cooperation and Development (OECD) countries (UK, France, Japan, and Korea) where supply-side and demand-side policies varied greatly, given high and ...
Yujeong Kim, Hye-Young Kwon, Hye-Young Kwon, Brian Godman, Brian Godman, Brian Godman, Evelien Moorkens, Steven Simoens, SeungJin Bae   +8 more
doaj   +1 more source

Switching Among Biosimilars: A Review of Clinical Evidence

Frontiers in Pharmacology, 2022
Biological medicines have improved patients’ outcomes, but their high costs may limit access. Biosimilars, alternatives that have demonstrated high similarity in terms of quality, safety, and efficacy to an already licensed originator biological product,
Eleonora Allocati, Brian Godman, Brian Godman, Brian Godman, Marco Gobbi, Silvio Garattini, Rita Banzi   +6 more
doaj   +1 more source

PGI12 Mean Annual Cost Of Patients Hospitalized For Chronic Hepatitis C In France: The Hepc-Lone Study [PDF]

, 2014
Las relaciones laborales marítimas se singularizan por caracteres que han propiciado la necesidad de formular instrumentos que tutelen los derechos de la gente de mar. Entre las singularidades más destacadas está el centro de trabajo: el buque.
Abergel, A., Rotily, M., Gaudin, A.F., De, Léotoing L., Vainchtock, A., Akremi, R., Branchoux, S.   +6 more
core   +3 more sources

Policy Networks and Policy Entrepreneurship in the EU: Explaining Structural Policy Change in Pharmaceutical Innovation Incentives and Health Technology Assessment

European Policy Analysis, EarlyView.
ABSTRACT Policy process research has excelled in explaining structural policy change within national settings, but extensions and applications to the EU level have long proven challenging for scholars. Given that the EU is currently experiencing its longest period of Treaty stability since the 1980s—having evolved into a sui generis political system ...
Vassilis Karokis‐Mavrikos
wiley   +1 more source

Therapeutic drug monitoring of CT-P13: a comparison of four different immunoassays [PDF]

, 2017
Background: The commercialization of CT-P13, an infliximab (IFX) biosimilar, has the potential to decrease health-related costs and enhance access to biological therapies.
Cláudia Camila Dias, Fernando Magro, Gonczi L, Helena Tavares de Sousa, Isadora Rosa, Joana Afonso, João Carvalho   +6 more
core   +1 more source

The Status and Emerging Developments in Laboratory Animal Science in Asia since 9th AFLAS Congress (2023) until 10th AFLAS Congress (2025)

Animal Models and Experimental Medicine, EarlyView.
Asian Federation of Laboratory Animal Science Associations (AFLAS)
wiley   +1 more source

Development of a step‐gradient simulated moving bed process for the polishing of monoclonal antibodies with anion exchange chromatography

Journal of Chemical Technology &Biotechnology, EarlyView.
Abstract BACKGROUND In recent years, biopharmaceutical applications in medicine have seen explosive growth and the need for efficient, rapid and inexpensive purification of these targets is the topic of tremendous research and development. The need to improve process efficiency has been an active area of investigation due to the tremendous potential ...
Yasmina MJ Harsy, Jonas Wege, Anthony Grabski, Romain Dabre, Egbert Müller, Carsten‐René Arlt   +5 more
wiley   +1 more source